The Charitable Access Program (CAP Program)
Genzyme Corporation
Contact Information
Cindy Ochs, R.N., B.S.N., CCM, Senior Case Management Specialist/CAP Program Manager
500 Kendall Street
Cambridge, MA 02142
1-(800) 745-4447 ext16634 (phone)
Cindy Ochs, R.N., B.S.N., CCM, Senior Case Management Specialist/CAP Program Manager
500 Kendall Street
Cambridge, MA 02142
1-(800) 745-4447 ext16634 (phone)
Physician requests should be directed to:
Genzyme Corp.
Wytske Kingma, M.D., Medical Affairs
500 Kendall Street
Cambridge, MA 02142
1-(800) 745-4447 ext16808 (phone)
Genzyme Corp.
Wytske Kingma, M.D., Medical Affairs
500 Kendall Street
Cambridge, MA 02142
1-(800) 745-4447 ext16808 (phone)
How to Apply:
Select one of the links below to download the application or go to the program site for more information on how to apply. Once you fill out your application, send it to the address on the application. Do NOT send it to RxResource.
Select one of the links below to download the application or go to the program site for more information on how to apply. Once you fill out your application, send it to the address on the application. Do NOT send it to RxResource.
Eligibility:
Based on financial and medical need. Must be uninsured and lack the financial means to purchase the drug. In order to maintain eligibility, patients and their families are expected to continue exploring alternative funding options with the Genzyme Case Management Specialist. These options include private insurance, government programs and/or charitable sources.
Based on financial and medical need. Must be uninsured and lack the financial means to purchase the drug. In order to maintain eligibility, patients and their families are expected to continue exploring alternative funding options with the Genzyme Case Management Specialist. These options include private insurance, government programs and/or charitable sources.
Other Information:
The CAP Program is considered a temporary funding program for patients who have lysosomal storage disorders.
The CAP Program is considered a temporary funding program for patients who have lysosomal storage disorders.
Product(s) covered by program:
- Aldurazyme®
- Ceredase
- Cerezyme®
- Fabrazyme®
- Myozyme®
